Skip to content
Catalyst

PapersPMID:22520937

Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 7 double-blind, placebo-controlled, randomized clinical trials.

Trials2012The record ↗

  1. Finding, moderate evidencelowersPostoperative atrial fibrillation incidence

What moved

1 findingHow to read these marks →
  • Decreases postoperative atrial fibrillation incidence

    moderatereplicated ×3

    “The pooled analysis showed that intravenous magnesium significantly reduced the incidence of POAF by 36% (RR 0.64; 95% CI 0.50-0.83; P = 0.001; Figure 2), with no heterogeneity between trials (heterogeneity P = 0.8; I2 = 0%).”
    Study
    meta-analysis
    Effect
    0.64 risk ratio, 95% CI 0.5 to 0.83
    Dose studied
    intravenous magnesium, total dose ranging from 8 to 100 mmol across trials (one trial not available)
    Population
    Adults undergoing coronary artery bypass grafting; pooled seven double-blind placebo-controlled randomized trials (placebo dextrose or saline infusion)

Study record

Design
meta-analysis
Species
human
Population
Adult patients undergoing coronary artery bypass grafting (CABG) in seven double-blind placebo-controlled randomized trials
Participants
1,028
Comparator
not stated in the paper / placebo
Duration
not reported
Endpoints measured
16
Declined
this platform holds no node for the endpoint